Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Prognostic Value Of DCE-MRI In Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Comparison With Traditional Survival Indicators

M. Pickles, M. Lowry, D. Manton, L. Turnbull
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
AbstractObjectivesTo determine associations between dynamic contrast-enhanced MR imaging (DCE-MRI) parameters and survival intervals in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy (NAC), surgery, and adjuvant therapies. Further, to compare the prognostic value of DCE-MRI parameters against traditional survival indicators.MethodsDCE-MRI and MR tumour volume measures were obtained prior to treatment and post 2nd NAC cycle. To demonstrate which parameters were associated with survival, Cox’s proportional hazards models (CPHM) were employed. To avoid over-parameterisation, only those MR parameters with at least a borderline significant result were entered into the final CPHM.ResultsWhen considering disease-free survival positive axillary nodal status (hazard ratio [HR] 6.79), younger age (HR 3.37), negative oestrogen receptor status (HR 3.24), pre-treatment Maximum Enhancement Index (MaxEI) (HR 6.51), and percentage change in MaxEI (HR 1.02) represented the retained CPHM covariates. Similarly, positive axillary nodal status (HR 11.47), negative progesterone receptor status (HR 4.37) and percentage change in AUC90 (HR 1.01) represented the retained predictive variables for overall survival.ConclusionsMultivariate survival analysis has demonstrated that DCE-MRI parameters obtained prior to NAC and/or post 2nd cycle can provide independent prognostic information that can complement traditional prognostic indicators available prior to treatment.Key points• MR-derived DCE-MRI parameters obtained prior to treatment have prognostic value. • Early treatment-induced reductions in DCE-MRI parameters represents a positive prognostic indicator. • DCE-MRI parameters provide independent prognostic information that can complement traditional prognostic indicators.
This paper references
10.1200/JCO.2005.02.6187
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
M. Kaufmann (2006)
10.1148/radiol.13121801
Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: association with dynamic contrast-enhanced MR imaging with computer-aided evaluation.
A. Yi (2013)
10.1002/jmri.21778
Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE‐MRI
Roar Johansen (2009)
10.1016/J.BREASTDIS.2013.01.023
Prognostic value DCE-MRI parameters in predicting factor disease free survival and overall survival for breast cancer patients
M. Su (2013)
10.1016/j.ejphar.2013.02.057
Current approaches for neoadjuvant chemotherapy in breast cancer.
R. Connolly (2013)
10.1002/jmri.23635
Correlation of perfusion parameters on dynamic contrast‐enhanced MRI with prognostic factors and subtypes of breast cancers
H. R. Koo (2012)
10.1371/journal.pone.0061969
MRI Enhancement in Stromal Tissue Surrounding Breast Tumors: Association with Recurrence Free Survival following Neoadjuvant Chemotherapy
E. Jones (2013)
10.1007/s10549-004-5819-2
Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy
M. Pickles (2004)
10.3109/02841851003782059
Prognostic value of pretreatment dynamic contrast-enhanced MR imaging in breast cancer patients receiving neoadjuvant chemotherapy: Overall survival predicted from combined time course and volume analysis
M. G. Heldahl (2010)
10.1016/j.ejrad.2008.05.007
Prognostic value of pre-treatment DCE-MRI parameters in predicting disease free and overall survival for breast cancer patients undergoing neoadjuvant chemotherapy.
M. Pickles (2009)
10.2214/AJR.184.6.01841774
MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.
S. Partridge (2005)
10.1007/s11523-010-0135-8
Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy
A. Padhani (2010)
10.1002/14651858.CD005002.PUB2
Preoperative chemotherapy for women with operable breast cancer.
J. Mieog (2007)
10.1038/nrc865
Metastasis: Dissemination and growth of cancer cells in metastatic sites
A. Chambers (2002)
10.1016/j.ejrad.2011.02.021
Prognostic value DCE-MRI parameters in predicting factor disease free survival and overall survival for breast cancer patients.
N. Tuncbilek (2012)
10.1034/J.1600-0455.2003.00080.X
Can contrast-enhanced MR imaging predict survival in breast cancer?
B. Bóné (2003)
GroomAC,MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites
AF Chambers (2015)
10.1371/journal.pone.0061550
Does Presence of a Mid-Ocean Ridge Enhance Biomass and Biodiversity?
I. Priede (2013)
10.1002/NBM.756
Assessing changes in tumour vascular function using dynamic contrast‐enhanced magnetic resonance imaging
C. Hayes (2002)
10.1148/radiol.11102493
Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy.
S. Li (2011)
10.1002/jmri.23812
Association between survival in patients with primary invasive breast cancer and computer aided MRI
M. Dietzel (2013)



This paper is referenced by
10.1007/s00330-019-06321-6
Dynamic contrast-enhanced MR imaging of the prostate: intraindividual comparison of gadoterate meglumine and gadobutrol
C. Lee (2019)
10.1186/s41747-019-0141-2
Textural radiomic features and time-intensity curve data analysis by dynamic contrast-enhanced MRI for early prediction of breast cancer therapy response: preliminary data
R. Fusco (2020)
10.1148/radiol.2017162823
Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer.
J. Wu (2017)
10.18383/j.tom.2016.00241
DCE-MRI Texture Features for Early Prediction of Breast Cancer Therapy Response
G. Thibault (2017)
10.1097/RLI.0000000000000222
Pretreatment Prognostic Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Vascular, Texture, Shape, and Size Parameters Compared With Traditional Survival Indicators Obtained From Locally Advanced Breast Cancer Patients
M. Pickles (2016)
10.18632/oncotarget.16482
Contrast agents in dynamic contrast-enhanced magnetic resonance imaging
Yuling Yan (2017)
10.1259/bjro.20180023
Differentiating the lymph node metastasis of breast cancer through dynamic contrast-enhanced magnetic resonance imaging
X. Dong (2019)
10.1148/RADIOL.2016152331
Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival.
M. Bae (2016)
10.2967/jnumed.116.174367
A Comparison of Near-Infrared Diffuse Optical Imaging and 18F-FDG PET/CT for the Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy
S. Jiang (2016)
10.1007/978-3-319-64638-1_4
Extravascular Contrast Agents
M. Mischi (2018)
10.1117/1.JMI.5.1.011011
Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging for predicting the response of locally advanced breast cancer to neoadjuvant therapy: a meta-analysis
J. Virostko (2018)
10.1148/radiol.2017162079
Computer-aided Diagnosis-generated Kinetic Features of Breast Cancer at Preoperative MR Imaging: Association with Disease-free Survival of Patients with Primary Operable Invasive Breast Cancer.
J. Kim (2017)
10.1016/j.tranon.2015.11.016
Early Prediction and Evaluation of Breast Cancer Response to Neoadjuvant Chemotherapy Using Quantitative DCE-MRI1
A. Tudorica (2016)
10.1117/1.JMI.5.1.014503
Use of clinical MRI maximum intensity projections for improved breast lesion classification with deep convolutional neural networks
Natalia Antropova (2018)
FOR : “ Near-infrared diffuse optical imaging ifor early prediction of breast cancer response to neoadjuvant chemotherapy : a comparative study using FDG-PET / CT
Shudong Jiang (2016)
10.1007/s00330-016-4670-2
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
Bang-Bin Chen (2016)
10.1016/j.clinimag.2017.10.016
Magnetic resonance (MR) features in triple negative breast cancer (TNBC) vs receptor positive cancer (nTNBC).
Giulia Angelini (2018)
10.1016/j.semradonc.2015.09.006
Incorporating Imaging Into the Locoregional Management of Breast Cancer.
A. Lourenco (2016)
10.1080/0284186X.2020.1830167
Neoadjuvant breast cancer treatment response; tumor size evaluation through different conventional imaging modalities in the NeoDense study
Ida Skarping (2020)
10.1007/s00330-019-06365-8
Whole-lesion histogram and texture analyses of breast lesions on inline quantitative DCE mapping with CAIPIRINHA-Dixon-TWIST-VIBE
K. Sun (2019)
10.1007/s00330-017-4850-8
Interim heterogeneity changes measured using entropy texture features on T2-weighted MRI at 3.0 T are associated with pathological response to neoadjuvant chemotherapy in primary breast cancer
Shelley A Henderson (2017)
10.1097/RLU.0000000000001274
Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI
Y. Kim (2016)
10.1007/s10120-016-0672-7
Assessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging
Lorena Consolino (2016)
10.1097/MD.0000000000012683
Diffuse optical spectroscopy for monitoring the responses of patients with breast cancer to neoadjuvant chemotherapy
Y. H. Liu (2018)
10.1093/jbi/wbaa084
A Novel Marker, Based on Ultrasound Tomography, for Monitoring Early Response to Neoadjuvant Chemotherapy.
N. Duric (2020)
Diagnostic value of dynamic contrast-enhanced magnetic resonance imaging and ultrasonography for differentiating between breast benign and malignant lesions : a comparative study
L. Wang (2017)
10.1371/journal.pone.0149279
Relating Doses of Contrast Agent Administered to TIC and Semi-Quantitative Parameters on DCE-MRI: Based on a Murine Breast Tumor Model
Menglin Wu (2016)
10.1016/j.acra.2018.06.014
Morphological and Semiquantitative Kinetic Analysis on Dynamic Contrast Enhanced MRI in Triple Negative Breast Cancer Patients.
S. Gigli (2019)
Transfer Learning in 4D for Breast Cancer Diagnosis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Qiyuan Hu (2019)
10.1016/j.cmpb.2017.12.015
Spatiotemporal features of DCE-MRI for breast cancer diagnosis
Masood Banaie (2018)
10.1259/bjr.20190712
Kinetic volume analysis on dynamic Contrast-enhanced MRI of Triple-Negative breast cancer: Associations with survival outcomes.
Yoko Hayashi (2019)
10.2967/jnumed.116.172759
18F-FDG PET–Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer
O. Humbert (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar